How will the ACR White Paper on Antimalarial Cardiac Toxicity affect your use of HCQ and CQ?

I am concerned about the recommendations in the paper and how it may open the door for unnecessary litigation against prescribing practitioners. HCQ associated QTc problems are a few case reports in number using the doses we use, while the doses used for COVID-19 studies were much higher than we use.